TB006
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
2
Sites
20
Countries
1
Endpoints
167
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 167 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 16 of 167 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
8
4
4
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05074498Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease | TB006 Alzheimer’s disease | Alzheimer's disease | Ph 1/2 | Completed | 18 | Oct 2022 | - | results |
| NCT05476783A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease | TB006 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Terminated | 13 | Nov 2023 | - | results |
| TB006SADSequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects | TB006 Alzheimer’s disease | Healthy volunteers | Ph 1 | Completed | 1 | May 2022 | - | |
| NCT05959239TB006 Expanded Access (EA) Compassionate Use | TB006 Alzheimer’s disease | Alzheimer's disease | Not applicable | Unknown | 0 | - | - |
Showing 1-4 of 4 trials